CounterX Therapeutics to Present at the 88th Annual College on Problems of Drug Dependence (CPDD) Scientific Meeting

Company leadership to highlight advances in the development of CTRX-101, a once-monthly monoclonal antibody for the prevention of fentanyl overdose and the company's pipeline SEATTLE, June 3, 2026 /PRNewswire/ -- CounterX Therapeutics, a biotechnology company focused on developing novel...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.